Talampanel With Standard Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma: A Multicenter Phase II Trial
PURPOSE: Recent data suggest that the glutamatergic system is important in the proliferation and migration of glioblastoma. Talampanel is a well-tolerated, oral α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor blocker that could be beneficial in this disease. PATIENTS AND METHODS...
Tallennettuna:
| Päätekijät: | , , , , , , , , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
American Society of Clinical Oncology
2009
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2734427/ https://ncbi.nlm.nih.gov/pubmed/19636006 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2008.21.6895 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|